Sectors
RPRX
Royalty Pharma plc
57.17
1 x 56.96
1 x 58.30
bid
ask
-
1.26
2.16%
undefined @ 04:00 PM
57.48 +0.31 (0.53%)
| Ytd | 47.96% | |
| 1y | 54.06% |
56.97
day range
58.29
34.08
52 week range
60.44
| Open | 58.06 | Prev Close | 58.43 | Low | 56.97 | High | 58.29 | Mkt Cap | 24.59B |
| Vol | 2.75M | Avg Vol | 3.65M | EPS | 5.07 | P/E | 11.28 | Forward P/E | 48.54 |
| Beta | 0.42 | Short Ratio | 3.14 | Inst. Own | 86.25% | Dividend | 0.94 | Div Yield | 1.60 |
| Ex Div Date | 08-14 | Earning | 08-05 | 50-d Avg | 56.11 | 200-d Avg | 46.44 | 1yr Est | 59.89 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-05 | 2026-06 | 1.27 | N/A | N/A | N/A |
| 2026-05-06 | 2026-03 | 1.21 | 1.3 | 0.09 | 7.44% |
| 2026-02-11 | 2025-12 | 1.29 | 1.46 | 0.17 | 13.18% |
| 2025-11-05 | 2025-09 | 0.99 | 1.17 | 0.18 | 17.71% |
| 2025-08-06 | 2025-06 | 1.03 | 1.14 | 0.11 | 10.68% |
| 2025-05-08 | 2025-03 | 0.95 | 1.06 | 0.11 | 11.23% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-07 | Citigroup | Upgrade | Buy | Buy |
| 2026-05-07 | JP Morgan | Upgrade | Overweight | Overweight |
| 2026-04-21 | UBS | Upgrade | Buy | Buy |
| 2026-04-10 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-01-30 | UBS | Upgrade | Neutral | Buy |
| 2026-01-27 | Citigroup | Upgrade | Buy | Buy |
Profile
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-29 | BASSLER BONNIE L | Director | 79.18K | Stock Award(Grant) |
| 2026-05-25 | COYNE TERRANCE P | Chief Financial Officer | 0.00 | Sale |
| 2025-05-12 | DESOUZA ERROL B | Director | 81.35K | Stock Award(Grant) |
| 2026-06-04 | ENGELBERT CATHERINE M. | Director | 55.67K | Stock Award(Grant) |
| 2025-06-29 | FERNANDEZ HENRY A | Director | 123.52K | Stock Award(Grant) |
| 2026-06-29 | HITE CHRISTOPHER | Officer | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Morgan Stanley - Brokerage Accounts | 43.57M | 0.00 | 9.83% |
| 2026-03-30 | Capital Research & Mgmt Co - Division 3 | 35.01M | 0.00 | 7.90% |
| 2026-03-30 | BlackRock Inc | 25.91M | 0.00 | 5.84% |
| 2026-03-30 | FMR Inc | 25.15M | 0.00 | 5.67% |
| 2026-03-30 | Baillie Gifford & Co Limited. | 16.16M | 0.00 | 3.64% |
| 2026-03-30 | State Street Corp | 10.99M | 0.00 | 2.48% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Capital Group New Perspective Comp | 19.65M | 0.00 | 4.43% |
| 2026-06-29 | American Funds New Perspective A | 19.65M | 0.00 | 4.43% |
| 2026-06-29 | American Funds Capital Inc Bldr A | 8.58M | 0.00 | 1.94% |
| 2026-06-29 | American Funds Growth Fd of Amer A | 7.58M | 0.00 | 1.71% |
| 2026-03-30 | Capital Group Growth Fnd of Amer Comp | 6.41M | 0.00 | 1.45% |
| 2026-03-30 | Morgan Stanley Inst Growth I | 5.21M | 0.00 | 1.18% |
Dividend
| Dividend | Date |
|---|---|
| 0.235 | 2026-08-14 |
| 0.235 | 2026-05-15 |
| 0.235 | 2026-02-20 |
| 0.22 | 2025-11-14 |
| 0.22 | 2025-08-15 |
| 0.22 | 2025-05-16 |
Split
| Split | Date |
|---|---|
| 0.25 : 1 | 2010-10-15 |